Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. - Wikidata - wikimedia - TriplyDB

Long-acting somatostatin analog therapy of acromegaly: a meta-analysis.

Long-acting somatostatin analog therapy of acromegaly: a meta-analysis.

http://www.wikidata.org/entity/Q34417750

about

Clinical importance of achieving biochemical control with medical therapy in adult patients with acromegaly Combined treatment of somatostatin analogues with pegvisomant in acromegaly Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly Need for improved monitoring in patients with acromegaly The effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegaly Meta-analysis on the effects of octreotide on tumor mass in acromegaly Lanreotide extended-release aqueous-gel formulation, injected by patient, partner or healthcare provider in patients with acromegaly in the United States: 1-year data from the SODA registry.Acromegaly clinical trial methodology impact on reported biochemical efficacy rates of somatostatin receptor ligand treatments: a meta-analysis.Prolactinomas, Cushing's disease and acromegaly: debating the role of medical therapy for secretory pituitary adenomas.Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension Clinical efficacy and safety results for dose escalation of somatostatin receptor ligands in patients with acromegaly: a literature review.Estrogen treatment for acromegaly.Long-term treatment with pegvisomant as monotherapy in patients with acromegaly: experience from ACROSTUDY Clinical applications of somatostatin analogs for growth hormone-secreting pituitary adenomas Results of endoscopic transsphenoidal pituitary surgery in 40 patients with a growth hormone-secreting macroadenoma Efficacy of lanreotide Autogel administered every 4-8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: a phase III trial.Identification of somatostatin receptor type 5 gene polymorphisms associated with acromegaly Medical therapy of acromegaly Long-term (up to 18 years) effects on GH/IGF-1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTa.Glycemic profile in patients with acromegaly treated with somatostatin analogue.Comparison of octreotide LAR and lanreotide autogel as post-operative medical treatment in acromegaly Differential somatostatin receptor (SSTR) 1-5 expression and downstream effectors in histologic subtypes of growth hormone pituitary tumors Resistance to somatostatin analogs in acromegaly: an evolving concept?Changing paradigms in the surgical and medical management of acromegaly.Medical treatment of acromegaly: comorbidities and their reversibility by somatostatin analogs.From somatostatin to octreotide LAR: evolution of a somatostatin analogue Cost of management of invasive growth hormone-secreting macroadenoma.Pegvisomant in acromegaly: why, when, how.Control of IGF-I levels with titrated dosing of lanreotide Autogel over 48 weeks in patients with acromegaly.Somatostatin agonists for treatment of acromegaly.Somatostatin analogs and gallstones: a retrospective survey on a large series of acromegalic patients.Guidelines for the treatment of growth hormone excess and growth hormone deficiency in adults.Cost-effectiveness of lanreotide Autogel in treatment algorithms of acromegaly.The role of primary pharmacological therapy in acromegaly.Octreotide LAR: safety and tolerability issues.Expression of Somatostatin Receptor 2 in Somatotropinoma Correlated with the Short-Term Efficacy of Somatostatin Analogues Pharmacokinetic evaluation of lanreotide.Medical therapy of acromegaly in Turkey.Medical therapy in acromegaly.Safety review: dose optimization of somatostatin analogs in patients with acromegaly and neuroendocrine tumors.

P2860

Q26741026-2F713C84-EC63-43B5-A3F1-1DBE6FD5FD34 Q26776366-BA35CFC6-B8F6-42CC-8627-6625F59598FF Q26777682-411B7405-6FAE-41E2-8D59-BF23677D11D8 Q26783670-15306D82-0F60-4AB8-9223-C2A6FC199042 Q26796357-EA603418-B5AE-4158-AEA2-161ADD4D70DE Q28730120-63BC4051-32D2-4C0B-95CB-0C4D14A0F9FB Q30585813-9B687A58-4B77-4E01-ACA3-82C12C911F3B Q33569037-25D4E788-6161-46BD-B238-372ECB10AA2E Q33579615-E30AA550-CCA4-41F6-B7CA-68020999D391 Q33595081-84AA5722-33F3-4BD3-8D01-A34ACB4339F8 Q33772673-7B4905BA-5F87-43EC-A134-AFF5AB9AB648 Q34296660-2A91F5EE-FCFD-406D-A636-F5E7A63D732F Q34446297-15DA393F-B5D3-41AD-804B-8F3961DE1502 Q34658946-14567D27-134D-4D22-A4FF-FA7A21D41F8A Q35036288-19C5CAED-5484-4728-8281-1AD011BB92D9 Q35104263-4586EA22-243E-420F-8EAA-0DD8E46A6588 Q35228807-120CBFAC-6C35-4627-9657-512D9C8B1E1C Q35895856-36632620-4C56-4213-8498-E56C380112FE Q35987482-2A55C244-975B-4398-9238-14005038FE59 Q36041450-B8E819D2-6401-4BE9-B1FE-1A394C60C149 Q36236809-EE820B0A-6160-43C7-835C-8435ED7BFC61 Q36270932-A5F95E06-56FC-4AE0-A61A-F172231431C6 Q36428225-29665E11-9876-42B3-B362-3601D513DE91 Q36605363-91F083A8-8BE6-4890-8297-8E5969339C09 Q36626503-F4E79A70-1EE1-4DEE-8BE6-D2B44B3EB05B Q36919554-A73CA062-CC3E-461F-919E-5C227F7ABA12 Q36937812-7A720D66-4588-4254-800A-117F91619117 Q36965612-B1901554-BA32-4319-AF05-306362A85083 Q37029532-87109120-8689-41CB-BFF6-702CFD975B84 Q37055643-2C1FD293-4D61-42C2-9581-232ABCB48C9C Q37292997-2FF42612-39A1-4259-86A4-5F0D142A1401 Q37321948-54477782-163A-4BCD-8039-33563D2D77BC Q37519612-B404BC5E-CD50-4FA8-9CEC-4E423D344429 Q37531005-B535544A-3DA5-4CFC-8BA9-8B3B2924776D Q37649647-993B5AF9-D11E-46EA-905C-AC9CE8289ABF Q37726440-522E6747-77E9-4DD8-ADDD-1D823443010A Q37780553-2A7E0883-9EB1-4EAB-A309-1361E2101755 Q37798655-0B212431-D5E7-4057-AE9F-97336D994DD1 Q37859250-E00D202A-18C9-453B-B974-7F3F74280C03 Q37941521-E701DADF-B16A-4EF2-BA78-CE08EA4A0AFA

P2860

Long-acting somatostatin analog therapy of acromegaly: a meta-analysis.

http://www.wikidata.org/entity/Q34417750

description

2005 nî lūn-bûn

@nan

2005 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Long-acting somatostatin analog therapy of acromegaly: a meta-analysis.

@ast

Long-acting somatostatin analog therapy of acromegaly: a meta-analysis.

@en

Long-acting somatostatin analog therapy of acromegaly: a meta-analysis.

@nl

type

label

Long-acting somatostatin analog therapy of acromegaly: a meta-analysis.

@ast

Long-acting somatostatin analog therapy of acromegaly: a meta-analysis.

@en

Long-acting somatostatin analog therapy of acromegaly: a meta-analysis.

@nl

prefLabel

Long-acting somatostatin analog therapy of acromegaly: a meta-analysis.

@ast

Long-acting somatostatin analog therapy of acromegaly: a meta-analysis.

@en

Long-acting somatostatin analog therapy of acromegaly: a meta-analysis.

@nl

P1433

Q34417750-14EB86D3-4B24-4D84-9244-863EED731001

P1476

Q34417750-29659837-2F64-4577-A48D-9BA386227DD7

P2093

Q34417750-12FEA118-B7E7-46FB-996C-E3F1C5BE6A0E

Q34417750-22F7EE68-585B-4F06-B6B1-10740FD52527

Q34417750-4B9D34D7-6359-43A5-8B47-160C6D2D2969

Q34417750-81DA6BA2-D46A-4A09-8AE3-7AC01738C3B8

Q34417750-D460C790-F11E-4870-9976-0C2FC1BDCD2B

Q34417750-EC585791-6190-4BB4-B658-9D7BBB515E64

P304

Q34417750-88B58148-AC8B-466D-9666-9825FEF77E30

P31

Q34417750-43d78ab9-4c08-4876-9e30-f285503173ad

Q34417750-94F0837E-ABC1-45E5-9598-FF4D1A38403A

P356

Q34417750-69B40F57-CB02-451E-AF19-F629992B1567

P407

Q34417750-32E691B6-B738-4C7E-AF03-906CCDC1C834

P433

Q34417750-59FB1556-09F2-404A-851B-05B26B95B578

P478

Q34417750-556E938F-7F18-4A08-AD8C-B3D7D44E1EAC

P577

Q34417750-7B2DD2B7-90B2-4ECE-8424-705652A9B194

P5875

Q34417750-BBF2B1C1-3236-4A80-AB79-AD452AD0D43F

P698

Q34417750-769691FA-5E2B-46A5-8E0B-1E18A074DEF9

P921

Q34417750-C9722075-C7D1-4A71-B18A-A2C353EA29C0

P356

P1433

The Journal of Clinical Endocrinology and Metabolism

P1476

Long-acting somatostatin analog therapy of acromegaly: a meta-analysis.

@en

P2093

Aart Jan van der Lely

http://www.w3.org/2001/XMLSchema#string

Carlos M Reyes

http://www.w3.org/2001/XMLSchema#string

Daniel Rabinowitz

http://www.w3.org/2001/XMLSchema#string

Laurence Katznelson

http://www.w3.org/2001/XMLSchema#string

Pamela U Freda

http://www.w3.org/2001/XMLSchema#string

Shouhao Zhao

http://www.w3.org/2001/XMLSchema#string

P304

4465-4473

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1210/JC.2005-0260

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

90

http://www.w3.org/2001/XMLSchema#string

P577

2005-05-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7855378

http://www.w3.org/2001/XMLSchema#string

P698

15886238

http://www.w3.org/2001/XMLSchema#string

P921